List of the 100 largest Immunology Venture Capital Investors [2024]


Features of Researchgermany

This list includes 101 immunology venture capital investors from our biotech venture capital investor list that mention the keyword immunology on their sites.

The list includes email addresses, investment focus, country information, corporate venture capital information, and investment focus. The list last updated on May 8th, 2024.

You can get a free preview file upon request via contact [at]


immunology investors list

List of 5 large Immunology Venture Capital Investors

In the following, we are highlighting five different interesting venture capital investors from our keyword crawler-based list that are covering immunology keywords on their websites.

1. Ascension Ventures (UK)

Ascension was voted Seed VC of the Year in 2022 by the UK Business Angels Association and is one of the most active investors in London. They focus on early-stage investments in the tech sector. One of their portfolio companies that focuses on immunology is AMLo which is developing prognostic cancer tests. Their first product is an immunohistochemical test that can identify tumors at low risk of recurrence.

Update 2024: Strive Health, a portfolio company, has recently closed a $166 million Series C financing round. The funding was led by NEA and included five new investors, among them strategic investor CVS Health Ventures. Joining them in the round were existing investors CapitalG (Alphabet), Echo Ventures, Town Hall Ventures, Ascension Ventures, and Redpoint.

2. Wellington Partners (Germany)

Since 1998 the company Wellington Partners has invested €590M in life science companies across 58 investments. Their investments typically range from €2M to €20M. Wellington Partners especially targets companies with an experienced management team and products that are in or close to clinical trials. One of these companies, for example, is Atopix. Atopix Therapeutics is developing small-molecule drugs to treat inflammatory and respiratory diseases.

3. Sofinnova Partners (France)

Established in 1972, the company has 50 years of experience in investment under their belt. Sofinnova Partners has backed over 500 companies and has €2.5Bn assets under management. The company mainly focuses on health tech start-ups, including Ablynx NV which developed Nanobodies®, meaning an antibody-derived therapeutic protein that can be used for a range of diseases including inflammation, hematology, and oncology.

4. Foresite Capital (USA)

Foresite Capital is a healthcare venture capital investor focused “on the forces driving healthcare transformation, and breakthrough companies that seek to transform their category”. It manages capital worth more than $3.5 Billion. Their portfolio for example includes among others Lyell Immunopharma, a cancer-treating-focused company with cellular therapies, whose goal is to develop curative cell-based immunotherapies for any cancer and solid tumors, Adaptimmune Therapeutics PLC, a clinical-stage biotech company focused on developing T cell therapies to treat cancer, and Aimmune Therapeutics Inc which is developing treatments to protect people with food allergies from the consequences of accidental exposure.

5. Tlv partners (Israel)

Tlv Partners has a broad investment range, but the majority of their health-sector-related investments are focused on immunology. There are for example CanopY and Immunai. CanopY for instance is developing a so-called “anti-vaccine” which is supposed to permanently delete an autoimmune response and relieve the patient from its disease. Its “Reverse-Immunization” platform utilizes computational protein design and systems immunology, integrated into a novel immunotherapeutic approach. Immunai tries to map the immune system with single-cell biology and AI to power new therapeutic discoveries, improve drug development, and improve patient outcomes.


There are no reviews yet.

Be the first to review “List of the 100 largest Immunology Venture Capital Investors [2024]”

Your email address will not be published. Required fields are marked *